Levodopa/Benserazide Hydrochloride

左旋多巴/盐酸苄丝肼

Report date: 2023/03/08 17:21:28

Base Information

Drug NameLevodopa/Benserazide Hydrochloride
Drug Alias Name盐酸苄丝肼/左旋多巴Benserazide Hydrochloride/LevodopaLevodopa and Benserazide Hydrochloride多巴丝肼Madopar
ClassificationSmall molecules
Mechanisms of ActionDopamine receptors agonistsDDC gene transferenceDOPA decarboxylase inhibitors
TargetsDopamine receptorsAromatic-L-amino-acid decarboxylase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaParkinson Disease
Original Approved Country/TerritorySwitzerland
Original Approved Date1973/06/27
Country/TerritoryPortugalGermanySwitzerland +[5] 
CombinationsYes LevodopaBenserazide Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdF. Hoffmann-La Roche LtdMax Planck Institute For Human Cognitive And Brain Sciences +[4] 
Inactive CompaniesBial - Portela C SaUniversity of Zurich
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN04BA02
Related LinksKEGG